Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU5416 in Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT00006361Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2000
- Primary completion
- Jan 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaxanib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Overall Survival at 1 year, Objective Response Rate at 1 year and 1 more. Started Dec 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00006361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006361.